Keros Therapeutics (KROS) Interest Expenses (2019 - 2025)

Keros Therapeutics' Interest Expenses history runs 7 years deep, the most recent figure standing at $98.0 million for Q4 2025.

• Quarterly Interest Expenses rose 10668.24% year-over-year to $98.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $98.0 million (up 58082.84% YoY) and the FY2025 annual result came in at $98.0 million, down 34.69% from the prior year.
• Interest Expenses was $98.0 million for Q4 2025 at Keros Therapeutics, up from $6.5 million in the prior quarter.
• Across five years, Interest Expenses topped out at $134.6 million in Q1 2024 and bottomed at -$880000.0 in Q4 2023.
• A 5-year average of $40.5 million and a median of $32.0 million in 2022 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses slumped 70000.0% — and 2024, when it jumped 26820.0%.
• Keros Therapeutics' Interest Expenses stood at $1000.0 in 2021, then slumped by 70000.0% to -$699000.0 in 2022, then declined by 25.89% to -$880000.0 in 2023, then jumped by 203.41% to $910000.0 in 2024, then soared by 10668.24% to $98.0 million in 2025.
• Business Quant data shows KROS's Interest Expenses at $98.0 million in Q4 2025, $6.5 million in Q3 2025, and $5.4 million in Q2 2025.